A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Summary

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).

Timeline

Start

2023-04-07

Primary completion

2026-02-06

Completion

2026-02-06

Publications

• Gibson CM, Bahit MC, Mehran R, Mehta SR, Lamee RA, Goto S, Weitz JI, Horrow J, Barnathan ES, Harrington RA, Mahaffey KW, Lam CSP, Pieper KS, Johnston SC, Hankey GJ, Plotnikov AN, Li D, Deng H, Steg PG; Librexia ACS Committees and Investigators.. Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS). Am Heart J. 2025 Jul;285:21-28. doi: 10.1016/j.ahj.2025.02.011. Epub 2025 Feb 20.

Drugs

Indications